Jobevne

BLA 761175, held by Biocon Biologics Inc. Bevacizumab-Nwgd.

As of Nov 13, 2026, BLA 761175 (Jobevne), held by Biocon Biologics Inc, was first approved by FDA on Apr 9, 2025, with 0 approved supplements and 0 published complete response letters.

First approved: Apr 9, 2025
Review: Standard
Supplements approved: 0
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

Jobevne is a vascular endothelial growth factor inhibitor indicated for the treatment of:

Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first-or second-line treatment.
Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use: Jobevne is not indicated for adjuvant treatment of colon cancer.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first

Date	Submission	Status	Documents
Apr 9, 2025	Original applicationNew formulation or manufacturer · Standard review	Approved	Review Label Letter

Products

2 strengths and forms

Product	Active ingredient	Marketing
Jobevne100MG/4ML · injectable;injection	Bevacizumab-Nwgd	Rx
Jobevne400MG/16ML · injectable;injection	Bevacizumab-Nwgd	Rx

Identifiers

Application: BLA 761175
Drugs@FDA: Overview at FDA
Company: Biocon Biologics

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters